Respiratory Medicine
Volume 96 , Pages S25-S29 , April 2002

The association between respiratory syncytial virus infection and reactive airway disease

  • G. PIEDIMONTE

      Affiliations

    • Departments of Pediatrics, Medicine, and Molecular/Cellular Pharmacology, University of Miami School of Medicine, Miami, FL, U.S.A.

References 

    REFERENCES
  1. MMWR Morb Mortal Wkly Rep. 2000;49:1091–1093
  2. Sims DG, Downham MA, Gardner PS. Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy. Br Med J. 1978;1:11–14
  3. Pullan CR, Hey EN. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. Br Med J. 1982;284:1665–1669
  4. McConnochie KM, Roghmann KJ. Bronchiolitis as a possible cause of wheezing in childhood: New evidence. Pediatrics. 1984;74:1–10
  5. Mok JY, Simpson H. Outcome for acute bronchitis, bronchiolitis, and pneumonia in infancy. Arch Dis Child. 1984;59:306–309
  6. Carlsen KH, Larsen S, Bjerve O. Acute bronchiolitic pre-disposing factors and characterization of infants at risk. Pediatr Pulmonol. 1987;3:153–160
  7. Murray M, Webb MS, O'Callaghan . Respiratory status and allergy after bronchiolitis. Arch Dis Child. 1992;67:482–487
  8. Osundwa VM, Dawod ST, Ehlayel M. Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis. Arch Dis Child. 1993;152:1001–1003
  9. Noble V, Murray M, Webb MS. Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child. 1997;76:315–319
  10. Moylett EH, Piedra PA. Respiratory syncytial virus infection: Diagnosis, treatment, and prevention. Hosp Med. 1999;35:10–17
  11. Stein RT, Sherrill D, Morgan WJ. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541–545
  12. Sigurs N, Bjarnason R, Sigurbergsson F. Respiratory syn-cytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507
  13. Piedimonte G, Rodriguez MM, King KA. Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol. 1999;277:L831–L840
  14. King KA, Hu C, Rodriguez MM. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol. 2001;24:101–107
  15. Piedimonte G, King KA, Holmgren NL. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Ped Res. 2000;47:351–356
  16. Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol (Lung Cell Mol Physiol). 2002;
  17. Simoes E AF. Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes. Am J Respir Crit Care Med. 2001;163:S14–S17
  18. Pediatrics. 1997;99:93–99
  19. Pediatrics. 1998;102:531–537
  20. Wenzel SE, Gibbs R, Lehr M. Asthma related clinical and physiologic outcomes in high risk children 5-9 years after prophylaxis with RSV-IGIV (abstract). Am J Respir Crit Care Med. 2000;161:A898
  21. Abbott Laboratories, Abbott Park, IL

PII: S0954-6111(02)91297-7

doi: 10.1053/rmed.2002.1297

Respiratory Medicine
Volume 96 , Pages S25-S29 , April 2002

Article Tools